{"id":"W2313460482","doi":"10.1136/annrheumdis-2014-eular.1885","title":"THU0262 Comparing Abatacept to Adalimumab, Etanercept and Infliximab as First or Second Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry","year":2014,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Osteoporosis Canada","funders":"","keywords":"Medicine; Adalimumab; Abatacept; Etanercept; Infliximab; Rheumatoid arthritis; Internal medicine; Cohort; TNF inhibitor; Rheumatology; Visual analogue scale; Discontinuation; Clinical trial; Physical therapy; Surgery; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006343549,0.0003785931,0.0016547,0.0006797383,0.0003080716,0.001529839,0.0008157725,0.0004641195,0.00603773],"category_scores_gemma":[0.0146677,0.0004606432,0.001623592,0.002166735,0.0003765489,0.001053648,0.0006932512,0.0009745409,0.0009131808],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008781528,"about_ca_system_score_gemma":0.00195505,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002661581,"about_ca_topic_score_gemma":0.005136001,"domain_scores_codex":[0.9911616,0.006364034,0.0009719109,0.0005929956,0.0006230498,0.0002864336],"domain_scores_gemma":[0.9888095,0.004748141,0.004247482,0.0008024234,0.0005391489,0.0008532068],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6469051,0.002017778,0.1560278,0.003620198,0.00806122,0.0002189261,0.0003773182,0.001365988,0.002469182,0.001014314,0.03539225,0.1425298],"study_design_scores_gemma":[0.3889145,0.06363698,0.4683594,0.002330926,0.01879614,0.001784198,0.0007408216,0.004216272,0.004708121,0.001469058,0.04483709,0.0002065999],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9067494,0.02757632,0.001244791,0.001444559,0.0004782484,0.001177054,0.04804219,0.0001972673,0.01309022],"genre_scores_gemma":[0.9430852,0.005466931,0.003122157,0.001110486,0.0004250815,0.001039678,0.0431997,0.00007157902,0.002479219],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006343549,"threshold_uncertainty_score":0.03354824,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06210309769386083,"score_gpt":0.3485165112373043,"score_spread":0.2864134135434434,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}